169 related articles for article (PubMed ID: 33917174)
1. Transcriptomic Profiles of CD47 in Breast Tumors Predict Outcome and Are Associated with Immune Activation.
Noblejas-López MDM; Baliu-Piqué M; Nieto-Jiménez C; Cimas FJ; Morafraile EC; Pandiella A; Corbi ÁL; Győrffy B; Ocaña A
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33917174
[TBL] [Abstract][Full Text] [Related]
2. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
3. NK Cell Infiltrates and HLA Class I Expression in Primary HER2
Muntasell A; Rojo F; Servitja S; Rubio-Perez C; Cabo M; Tamborero D; Costa-García M; Martínez-Garcia M; Menéndez S; Vazquez I; Lluch A; Gonzalez-Perez A; Rovira A; López-Botet M; Albanell J
Clin Cancer Res; 2019 Mar; 25(5):1535-1545. PubMed ID: 30523021
[TBL] [Abstract][Full Text] [Related]
4. In silico transcriptomic mapping of integrins and immune activation in Basal-like and HER2+ breast cancer.
Rojas K; Baliu-Piqué M; Manzano A; Saiz-Ladera C; García-Barberán V; Cimas FJ; Pérez-Segura P; Pandiella A; Győrffy B; Ocana A
Cell Oncol (Dordr); 2021 Jun; 44(3):569-580. PubMed ID: 33469836
[TBL] [Abstract][Full Text] [Related]
5. Co-expression modules identified from published immune signatures reveal five distinct immune subtypes in breast cancer.
Amara D; Wolf DM; van 't Veer L; Esserman L; Campbell M; Yau C
Breast Cancer Res Treat; 2017 Jan; 161(1):41-50. PubMed ID: 27815749
[TBL] [Abstract][Full Text] [Related]
6. Natural Killer Cell Recruitment and Activation Are Regulated by CD47 Expression in the Tumor Microenvironment.
Nath PR; Pal-Nath D; Mandal A; Cam MC; Schwartz AL; Roberts DD
Cancer Immunol Res; 2019 Sep; 7(9):1547-1561. PubMed ID: 31362997
[TBL] [Abstract][Full Text] [Related]
7. Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα-CD47 innate immune checkpoint.
Voets E; Paradé M; Lutje Hulsik D; Spijkers S; Janssen W; Rens J; Reinieren-Beeren I; van den Tillaart G; van Duijnhoven S; Driessen L; Habraken M; van Zandvoort P; Kreijtz J; Vink P; van Elsas A; van Eenennaam H
J Immunother Cancer; 2019 Dec; 7(1):340. PubMed ID: 31801627
[TBL] [Abstract][Full Text] [Related]
8. Dual blockade of CD47 and HER2 eliminates radioresistant breast cancer cells.
Candas-Green D; Xie B; Huang J; Fan M; Wang A; Menaa C; Zhang Y; Zhang L; Jing D; Azghadi S; Zhou W; Liu L; Jiang N; Li T; Gao T; Sweeney C; Shen R; Lin TY; Pan CX; Ozpiskin OM; Woloschak G; Grdina DJ; Vaughan AT; Wang JM; Xia S; Monjazeb AM; Murphy WJ; Sun LQ; Chen HW; Lam KS; Weichselbaum RR; Li JJ
Nat Commun; 2020 Sep; 11(1):4591. PubMed ID: 32929084
[TBL] [Abstract][Full Text] [Related]
9. Identification of immunological subtypes of hepatocellular carcinoma with expression profiling of immune-modulating genes.
Cao D; Chen MK; Zhang QF; Zhou YF; Zhang MY; Mai SJ; Zhang YJ; Chen MS; Li XX; Wang HY
Aging (Albany NY); 2020 Jun; 12(12):12187-12205. PubMed ID: 32544882
[TBL] [Abstract][Full Text] [Related]
10. A favorable role of prolactin in human breast cancer reveals novel pathway-based gene signatures indicative of tumor differentiation and favorable patient outcome.
Hachim IY; Shams A; Lebrun JJ; Ali S
Hum Pathol; 2016 Jul; 53():142-52. PubMed ID: 26980025
[TBL] [Abstract][Full Text] [Related]
11. Expression and significance of CD47, PD1 and PDL1 in T-cell acute lymphoblastic lymphoma/leukemia.
Yang K; Xu J; Liu Q; Li J; Xi Y
Pathol Res Pract; 2019 Feb; 215(2):265-271. PubMed ID: 30466764
[TBL] [Abstract][Full Text] [Related]
12. Concurrent Expression of CD47 and CD44 in Colorectal Cancer Promotes Malignancy.
Fujiwara-Tani R; Sasaki T; Ohmori H; Luo Y; Goto K; Nishiguchi Y; Mori S; Nakashima C; Mori T; Miyagawa Y; Kawahara I; Fujii K; Kishi S; Tatsumoto N; Kuniyasu H
Pathobiology; 2019; 86(4):182-189. PubMed ID: 31132784
[TBL] [Abstract][Full Text] [Related]
13. Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness.
Miller LD; Chou JA; Black MA; Print C; Chifman J; Alistar A; Putti T; Zhou X; Bedognetti D; Hendrickx W; Pullikuth A; Rennhack J; Andrechek ER; Demaria S; Wang E; Marincola FM
Cancer Immunol Res; 2016 Jul; 4(7):600-10. PubMed ID: 27197066
[TBL] [Abstract][Full Text] [Related]
14. The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer.
Matlung HL; Szilagyi K; Barclay NA; van den Berg TK
Immunol Rev; 2017 Mar; 276(1):145-164. PubMed ID: 28258703
[TBL] [Abstract][Full Text] [Related]
15. Immune signature of metastatic breast cancer: Identifying predictive markers of immunotherapy response.
Kim JY; Lee E; Park K; Park WY; Jung HH; Ahn JS; Im YH; Park YH
Oncotarget; 2017 Jul; 8(29):47400-47411. PubMed ID: 28537889
[TBL] [Abstract][Full Text] [Related]
16. Transcriptomic immunologic signature associated with favorable clinical outcome in basal-like breast tumors.
Martínez-Canales S; Cifuentes F; López De Rodas Gregorio M; Serrano-Oviedo L; Galán-Moya EM; Amir E; Pandiella A; Győrffy B; Ocaña A
PLoS One; 2017; 12(5):e0175128. PubMed ID: 28472085
[TBL] [Abstract][Full Text] [Related]
17. CD47 expression in gastric cancer clinical correlates and association with macrophage infiltration.
Shi M; Gu Y; Jin K; Fang H; Chen Y; Cao Y; Liu X; Lv K; He X; Lin C; Liu H; Li H; He H; Qin J; Li R; Zhang H; Zhang W
Cancer Immunol Immunother; 2021 Jul; 70(7):1831-1840. PubMed ID: 33389016
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Implication of Urothelial Stem Cell Markers Differs According to Primary Tumour Location in Non-Muscle-Invasive Bladder Cancer.
Wang L; Zhao J; Yang C; Kuang R; Kazobinka G; Pang Z; Hou T
Cell Physiol Biochem; 2018; 48(6):2364-2373. PubMed ID: 30114689
[TBL] [Abstract][Full Text] [Related]
19. A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast Tumors.
Pérez-Pena J; Tibor Fekete J; Páez R; Baliu-Piqué M; García-Saenz JÁ; García-Barberán V; Manzano A; Pérez-Segura P; Esparis-Ogando A; Pandiella A; Gyorffy B; Ocana A
Front Immunol; 2019; 10():2802. PubMed ID: 31921107
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 expression and CD8-positive T cells are associated with favorable survival in HER2-positive invasive breast cancer.
Hou Y; Nitta H; Wei L; Banks PM; Lustberg M; Wesolowski R; Ramaswamy B; Parwani AV; Li Z
Breast J; 2018 Nov; 24(6):911-919. PubMed ID: 30230111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
